Cell proliferation is controlled by cdk2 which in association with cyclin E and A regulates G1/S transition and S phase progression. cdk2 activation is dependent on its localization in the nucleus where regulatory mediators are found. We report that activation of cdk2 is associated with the formation of cdk2/ MAP Kinase complexes. cdk2 associates with both inactive and activated MAP Kinase. Prevention of MAP Kinase activation by the MEK inhibitor PD98059 inhibits both activation and nuclear localization of cdk2 and S phase entry. These ®ndings indicate that the nuclear translocation of cdk2 is associated with the formation of molecular complexes containing active MAP Kinase and is dependent on MAP Kinase activation. Oncogene (2000) 19, 4184 ± 4189.
Cell cycle progression in mammalian cells is under the control of a family of serine/threonine kinases named the cyclin-dependent kinases (cdk) (Fisher, 1997; Morgan, 1995) . Activation of cdk is regulated by their association with regulatory subunits (the cyclins), and cdk inhibitors, and phosphorylation or dephosphorylation of particular residues (Lew and Kornbluth, 1996; Morgan, 1995; Reed, 1997; Sherr and Roberts, 1995) . Activated cdk/cyclin complexes that control G1 and S phases (Cyclin D-cdk4/6 and Cyclin E/A-cdk2) are mainly found in the nucleus where their speci®c substrates are present (Bresnahan et al., 1996; Fotedar et al., 1996; Ohtsubo et al., 1995; Pines and Hunter, 1994; Prosperi et al., 1997; Weinberg, 1995) .
Translocation of cdk to the nucleus contributes to the regulation of their activity as appropriate association with the speci®c cyclin and interaction with regulatory kinases and phosphatases depend on this localization. For instance, the regulatory complex, named cdk Activating Kinase (CAK), which controls the phosphorylation of cdk2 residue Thre 160 is located in the nucleus where it is constitutively activated (Labbe et al., 1994; Matsuoka et al., 1994; Tassan et al., 1994) . Similarly, the phosphatase family (CDC25) responsible for the activatory dephosphorylation of cdk2 residue Tyr-15 can also be localized in the nucleus (Homann et al., 1994; Honda et al., 1993; Jinno et al., 1994; Strausfeld et al., 1991) . The mechanisms responsible for the transport of cdk and cyclins from cytoplasm to nucleus are still poorly understood. Besides the G2/M regulatory cyclin B which contains a`nuclear export sequence' (Yang et al., 1998 ) the other cyclins and cdks which control G1 and S phases are mostly localized in the nucleus but do not contain typical`nuclear localization signal' sequences (NLS) required for the transport of many proteins (Gorlich and Mattaj, 1996; Nigg, 1997; Pines and Hunter, 1994) . Therefore their translocation to the nucleus probably depends on their association with partner or carrier proteins containing an NLS sequence or not.
Entry into and progression through S phase is mainly controlled by cdk2, which associates sequentially with cyclin E during G1/S transition and cyclin A for the S phase progression (Dulic et al., 1992; Rosenblatt et al., 1992) . However, other kinases may in¯uence G1/S progression. Several groups have reported that sustained activation of the serine/ threonine Mitogen Activated Protein Kinase (MAP Kinase) is necessary to induce proliferation of various cell types and Brunet et al. recently demonstrated that cytoplasmic retention of activated MAP Kinase was sucient to prevent cell cycle re-entry (Brunet et al., 1999; Cowley et al., 1994; Mansour et al., 1994; Meloche et al., 1992; Pages et al., 1993) . We previously observed that MAP Kinase speci®cally associates with other kinases such as the src tyrosine kinase p56 lck depending on the cell cycle phase (Taieb et al., 1995) . However, no direct interactions between MAP Kinase and cdk/cyclins complexes have been reported. This led us to investigate possible interactions between MAP Kinase and cdk2 during the control of IL-2-dependent proliferation of the human T cell line Kit 225 (Hori et al., 1987) .
Growth factor deprivation of Kit 225 cells led to their becoming arrested in G1 (Figure 1a) . Such arrested cells entered S phase 20 h after IL-2 restimulation ( Figure 1a ) and this was associated with the expression of cdk2 which is very low in G1 arrested cells (Figure 1b) . cdk2 is present in IL-2 activated cells in both inactive and active forms. Active cdk2 is visualized as a 33 kDa, faster migrating band corre- Oncogene (2000) 19, 4184 ± 4189 ã 2000 Macmillan Publishers Ltd All rights reserved 0950 ± 9232/00 $15.00 www.nature.com/onc sponding to Tyr 15 dephosphorylated cdk2 . We next veri®ed whether S phase entry and cdk2 activation were associated with direct interaction between cdk2 and MAP Kinase. Indeed, MAP Kinase coimmunoprecitated with cdk2 from total (non fractionated) cell lysate of Kit 225 cells activated with IL-2, with a steady time-dependent increase ( Figure  1b) . Western blotting analyses demonstrated the presence of MAP Kinase in the cdk2 immune complexes prepared from IL-2-activated cells whereas no MAP Kinase was detected in control immune complexes formed with control rabbit Ig (Figure 1c) . We next tested whether MAPK could associate to the cdk2/cyclin E complex. For this, cell lysates from 24 h-IL-2-activated T cells were immunoprecipated with anti-cyclin E or Ig control and subjected to immunoblotting with anti-MAPK Ab. MAPK was associated with the cyclin E probably through the cyclinE/cdk2 complex (Figure 1d ). Cytoplasm and nuclei were next separated by cell fractionation and active cdk2 (visualized as the faster migrating band of 33 kDa) was only detected in the nucleus whereas the 34 kDa inactive form was present in both cytoplasm and nucleus ( Figure 1e ). In contrast, 12% SDS ± PAGE revealed active ERK2/MAP Kinase (visualized as a 43 kDa, upper band in Figure 1e , corresponding to phosphorylated ERK2/MAP Kinase (Leevers and Marshall, 1992) in both cytoplasmic and nuclear fractions of IL-2-activated Kit 225 cells. leupeptin, 2 mg ml 71 pepstatin A, 100 mg ml 71 soybean trypsin inhibitor, 50 mM NaF, 30 mM pyrophosphate and 50 mM b-glycerophosphate). Lysates were immunoprecipated with either agaroseconjugate anti-cdk2 Ab anti-cyclin E or control rabbit Ig coated on Protein G sepharose beads. Immune complexes were resolved by 10% (37.5% acrylamide/1% Bis-acrylamide) SDS ± PAGE before electroblotting and incubation with speci®c rabbit anti-ERK2/MAP Kinase and anti-cdk2 Ab successively. Cytoplasmic and nuclear extract preparations were tested for MAP Kinase and cdk2 expression. Cells were incubated for 3 min at 48C in lysis buer A (50 mM Tris pH 7.5, 140 mM NaCl, 0.05% NP-40, 5 mM MgCl 2 , 5 mM CaCl 2 , 5% glycerol, 1 mg ml 71 aprotinin, 10 mg ml 71 leupeptin, 2 mg ml 71 pepstatin A, 100 mg ml 71 soybean trypsin inhibitor, 50 mM NaF, 30 mM pyrophosphate and 50 mM b-glycerophosphate), lysates were centrifuged for 4 min at 2000 r.p.m. and supernatants (cytoplasmic fraction) were recovered. Nuclear fractions were obtained by lysis of cell pellets with buer B. Both cytoplasmic and nuclear fractions were centrifuged for 15 min at 13 000 r.p.m. Equal amounts of cytoplasmic and nuclear proteins were then resolved by 12.5% (30% acrylamide/0.2% Bisacrylamide) SDS ± PAGE before electroblotting and incubation with speci®c rabbit anti-ERK2/MAP Kinase Ab. Blots were stripped and reblotted with rabbit anticdk2 Ab and developed using ECL system. MAP Kinase appears as two bands of 42 and 43 kDa and cdk2 as 33 and 34 kDa bands (e) were subjected to immunoprecipitation with cdk2 Ab. Immune complexes were run on a 12.5% (30% acrylamide/0.2% Bis-acrylamide) SDS ± PAGE gel, transferred to ®lters and ®lters were blotted with anti-ERK2/MAP Kinase Ab (c). Total cell lysate from 30 h IL-2-stimulated Kit 225 cells was immunoprecipitated by cdk2 Ab and subjected (phosph.) or not (7) to in vitro dephosphorylation with acid phosphatase (1 u/ml) for 25 min in 20 mM HEPES pH 6, 1% Triton, 10 mM EDTA buer. Western blotting was used to analyse the immunoprecipitates as in a. (d) cdk2 or control rabbit Ig immune complexes were washed twice with kinase buer (150 mM NaCl, 50 mM HEPES pH 7.5, 1 mM EDTA, 1 mM EGTA, 50 mM NaF, 2 mM sodium vanadate, 1 mg/ml aprotinin, 2 mM PMSF, 1 mM DTT, 10 mg/ml leupeptin, 2 mg/ml pepsatin A) and suspended in a total volume of 40 ml kinase buer containing 5 mCi of [g-32 P]ATP (3000 Ci/mmol) and 2.5 mg of recombinant GST-elk1 protein. After 30 min at 378C, SDS ± PAGE sample buer was added, the samples heated to 1008C for 5 min, run on a 10% SDS polyacrylamide gel, electroblotted and autoradiographed (g-32 P Assay GST-elk). After the disappearance of radioactivity, the membrane was further probed with an anti-GST Ab (Western GST)
We next investigated the cellular localization of this cdk2/MAP Kinase complex (Figure 2 ). ERK2/MAP Kinase associated with cdk2 was found both in cytoplasmic and in nuclear fractions, although the majority of cdk2-associated MAP Kinase was in the cytoplasmic fraction (Figure 2a,b) . cdk2-associated MAP Kinase in the cytoplasmic fraction was present in both inactive (42 kDa) and active forms of ERK2/ MAP Kinase (43 kDa). In contrast, only the inactive 42 kDa form of MAP Kinase was associated with cdk2 in the nuclear fraction (Figure 2a,b) . We then veri®ed that, under the experimental conditions used, the 43 kDa form of MAP Kinase associated with cdk2 was the phosphorylated active form MAP Kinase. In vitro treatment of the cdk2 immune complex with acid phosphatase led to disappearance of the 43 kDa MAP Kinase species (Figure 2c ). Thus the 43 kDa form of MAP Kinase associated with cdk2 is a phosphorylated form of MAP Kinase. Furthermore, the cdk2 immune complex was able to phosphorylate in vitro recombinant GST-elk-1 protein, a speci®c substrate for MAP Kinase (Gille et al., 1992; Janknecht et al., 1993; Marais et al., 1993; Ruckdeschel et al., 1997) (Figure  2d ). Thus, our data show that cdk2 directly associates with phosphorylated and therefore active MAP Kinase in cells entering S phase.
We next investigated whether activation of cdk2 and formation of the cdk2/MAP Kinase complex were dependent on MAP Kinase activation (Figure 3 ). For this, IL-2-stimulated Kit 225 cells were cultured in the presence of a speci®c inhibitor (PD98059) of the MAP Kinase Kinase (MEK). Activation of MAP Kinase requires the dual phosphorylation of Tyr-185 and Thre-183 residues by MEK and inactivation of MEK by PD98059 prevents further activation of MAP Kinase (Alessi et al., 1995; Crews et al., 1992; Dudley et al., 1995) . To study the role of MAP Kinase during the control of S phase entry, we added PD98059 6 h after IL-2 stimulation. Under these conditions, early phases of cell activation dependent on MAPK activation, such as upregulation of Cyclin D3 or down regulation of P27 Kip1 , were not modi®ed by this late addition of PD98059 (Figure 3a) . Addition of PD98059 after 6 h of culture did not prevent IL-2-mediated up regulation of cdk2 expression (Figure 3b ). Nevertheless, the 33 kDa form of cdk2 was not detected by Western blotting in the presence of PD98059 indicating that cdk2 remains inactive. Inhibition of cdk2 activation by PD98059 was veri®ed by standard in vitro kinase assays using histone H1 as substrate (Figure 3c ). cdk2 was then immunoprecipitated 28 h after IL-2-activation when cells were entering the S phase. Under these conditions, no 43 kDa form of activated MAP Kinase was detected in the cdk2 immune complex. In contrast, the 42 kDa form of MAP Kinase was still associated with cdk2 ( Figure 3d) . Thus, the association between MAP Kinase and cdk2 is not dependent on MAP Kinase being activated. cdk2 may associate directly with both activated and inactivated MAP Kinase or alternatively MAP Kinase activation may take place after its association with cdk2. As the 43 kDa MAP Kinase form was only associated with cdk2 in the cytoplasmic fractions (Figure 2) , activation of cdk2-associated MAP Kinase may occur in the cytoplasm, consistent with the cytoplasmic localization of MEK (Fukuda et al., 1996; Lenormand et al., 1993) .
When PD98059 was added 6 h after IL-2 stimulation, cells remains arrested in G1 (8% in S phase as opposed to 45% in controls, Figure 3b ). These data strongly suggest that upon IL-2 stimulation, MEK-dependent The MEK inhibitor PD98059 (50 mM in DMSO) or an equal concentration of DMSO (1/1000) were added to the cultures after 6 h of IL-2 activation. Cell lysates (50 mg) from cell activated in the presence of the inhibitor (PD98059) or control DMSO (control) were tested for Cyclin D3 and p27 by immunoblotting with speci®c anti-cyclin D3 or anti-p27 Ab. The amount of protein loaded in each lane was assessed by rehybridization of the ®lter with an Ab speci®c for human actin (a). Quanti®cation of the percentage of cells in S phase and anti-cdk2 Western blot analysis were performed in cells either not activated (0) or stimulated by IL-2 in the presence of PD98059 or control DMSO (7). (b) Total cell lysates from cell activated in the presence of the inhibitor (PD98059) or control DMSO (control) were immunoprecipitated by cdk2 Ab and subjected to Western analysis with anti-cdk2 (b) or ERK2/MAP Kinase Ab (d). cdk2 kinase activity was determined in cells activated for 28 h with IL-2 in the presence and absence of PD98059. Kinase assays were as in Figure 2 using histone H1 as substrate and reprobing the membrane with cdk2 Ab (c) activation of MAP Kinase occurs also throughout G1 phase. Thus inhibition of MAP Kinase activation does not prevent its association with cdk2 but prevents cdk2 activation and subsequent S phase entry.
Since phosphorylated MAP Kinase translocates to the nucleus (Brunet et al., 1999; Khokhlatchev et al., 1998) and complete cdk activation takes place within the nucleus, we investigated the ability of PD98059 to modulate the cellular localization of cdk2 (Figure 4) . Using confocal microscopic and biochemical approaches, we ®rst veri®ed that cdk2 was present in both the cytoplasm and nucleus of cells activated for 28 h with IL-2 (Figure 4a,b) and absent from G1 arrested cells (Figures 1 and 4a) . In contrast, in the presence of PD98059, which abolishes the association of cdk2 with active MAP Kinase (Figure 3a) , cdk2 was found in the cytoplasm and its concentration in the nucleus was signi®cantly lower than that in cells activated with IL-2 in the absence of PD98059 (Figure  4a,b) . Scan analysis (Figure 4b ) demonstrated that whereas cdk2 in cells activated without PD98059 was present in a comparable amount in cytoplasmic and nucleic fractions, in contrast, cdk2 express in cells activated with IL-2 in the presence of PD98059 was mostly in the cytoplasmic fraction. Thus, these data strongly suggest that translocation of cdk2 to the nucleus requires activation of MAP Kinase and is associated with the formation of phosphorylated MAP Kinase/cdk2 complexes.
It has recently been reported that translocation of MAP Kinase to the nucleus requires phosphorylation of MAP Kinase (Brunet et al., 1999; Khokhlatchev et al., 1998) . This transport involves the formation of homodimers including at least one phosphorylated MAP Kinase molecule. Phosphorylated MAP Kinase can associate with either phosphorylated or non phosphorylated MAP Kinase and promotes their translocation to the nucleus behaving as a nuclear transport factor. Our data demonstrate that MAP Kinase can also directly in¯uence the cellular localization of cell cycle regulator molecules such as cdk2. We observed that transport of cdk2 to the nucleus is dependent on its association with MAP Kinase phosphorylated by MEK on Tyr-185 and Thre-183 Anderson et al., 1990; Nakielny et al., 1992; Payne et al., 1991; Rossomando et al., 1992) . Although this dual phosphorylation is sucient to translocate MAP kinase (Brunet et al., 1999; Khokhlatchev et al., 1998) , it remains to be determined whether additional phosphorylations are necessary for MAP Kinase-associated cdk2 nuclear translocation. Indeed other kinases, such as the src kinase p56lck, which are able to phosphorylate MAP Kinase in vitro (Ettehadieh et al., 1992) , form complexes with MAP Kinase during the S phase entry (Taieb et al., 1995) and therefore may also be involved in the phosphorylation-mediated modi®cations of MAP Kinase necessary for its involvement during cdk2 nuclear translocation.
Other molecules may also be involved during this process. In the cytoplasm, cdk form molecular complexes comprising their speci®c cyclins, cdk inhibitors and not yet identi®ed molecules (Diehl and Sherr, 1997; Mahony et al., 1998) . The formation of these complexes could explain why nuclear translocation of cdk requires an active process involving partner molecules including MAP Kinase and is not simple diusion into the nucleus as for other proteins smaller than 40 ± 50 kDa (Gorlich Figure 3 , PD98059 (50 mM) or control DMSO was added to the cultures after 6 h of IL-2 stimulation. Cells were harvested after 28 h of culture and the cellular sub-localization of cdk2 was analysed by confocal microscopy. (a) Cells were cytospun and ®xed at 7208C for 10 min with a methanol/acetone (70 : 30). After rehydratation for 10 min at room temperature in PBS+10% fetal calf serum, cells were incubated with rabbit anti-cdk2 Ab (0.5 mg/ml) for 1 h. Cells were washed three times with PBS and incubated with goat ant-rabbit FITC-conjugated Ab (1/50). Cells were washed ®ve times with PBS, mounted under glass with resolving medium and analysed by confocal microscopy. (b) In parallel experiments, cytoplasmic and nuclear fractions were prepared from cells treated or not with PD98059. cdk2 was analysed by Western blotting as described for Figure 1 and relative amounts of cdk2 proteins in cytoplasmic and nuclear fractions were determined by scanning densitometry and Mattaj, 1996) . Among molecules able to associate with cdk2, the cdk inhibitor p21 cip possess in its sequence a NLS motif (el-Deiry et al., 1993; Harper et al., 1993) and it has been reported that, at low concentrations, p21 cip can facilitate the assembly of active cdk4/cyclin D1 complexes in vitro and in vivo promoting their nuclear localization (LaBaer et al., 1997) . Since upregulation of p21 cip expression has been observed during IL-2-induced T cell proliferation (Nourse et al., 1994) , we are investigating whether in association with MAP Kinase, p21 cip or other molecules can in¯uence the cellular localization of cdk2. In conclusion, our data show that nuclear translocation of cdk2 and the resulting G1/S transition of IL-2-dependent Kit 225 T cells is directly associated with the physical interaction of cdk2 with MAP Kinase and dependent on MAP Kinase activation.
